Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HuM195-Gelonin Purging in AML/MDS ASCT
NCT00043810Phase 2Terminated
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jul 2002
- Primary completion
- Mar 2005
- Modality
- Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of HuM-195 + recombinant gelonin in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Optimal Dose of HuM195-Gelonin Conjugate. Started Jul 2002; status: terminated.
02
Drugs
HuM-195 + recombinant gelonin
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT00043810.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00043810.